Rezistin

Rezistin
Rezistin
	Kristalografska struktura heksamera mišjeg rezistina (N-terminus = plavo, C-terminus = crveno).
Dostupne strukture
	1rfx, 1rgx
Identifikatori
Simboli	RETN; ADSF; FIZZ3; MGC126603; MGC126609; RETN1; RSTN; XCP1
Vanjski ID	OMIM: 605565 MGI: 1888506 HomoloGene: 10703 GeneCards: RETN Gene
Ontologija gena
Molekularna funkcija	• hormonska aktivnost;
Celularna komponenta	• ekstracelularni region;
Biološki proces	• biološki proces;
Pregled RNK izražavanja
	podaci
Ortolozi
Vrsta	Čovek
Entrez	56729
Ensembl	ENSG00000104918
UniProt	Q9HD89
RefSeq (mRNA)	NM_020415
RefSeq (protein)	NP_065148
Lokacija (UCSC)	Chr 19:; 7.64 - 7.64 Mb
PubMed pretraga	[1]

Rezistin (sekretorni faktor specifičan za adipozno tkivo, ADSF, (engl. C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein), XCP1) je protein bogat cisteinom koji je kod ljudi kodiran RETN genom.^[2]

Kod primata, svinja, i pasa, rezistin izlučuju imune i epitelne ćelije, dok ga kod glodara izlučuje adipozno tkivo. Dužina rezistinskog prepeptida kod ljudi je 108 aminokiselina, a kod miševa i pacova 114 aminokiselina. Molekulska masa je ~12.5 kDa. Rezistin je citokin čija fiziološka uloga je bila kontroverzna u pogledu njegovog uticaja na gojaznost i tip II dijabetes melitus.^[3]

Otkriće уреди

Rezistin je otkrila grupa predvođena dr Mičelom Lazarom 2001 na Univerzitetu Pensilvanije u Školi za Medicinu.^[4] On je dobio ime „rezistin“ zato što je primećena insulinska rezistencija kod miševa nakon ubrizgavanja rezistina. Utvrđeno je da rezistin proizvodi i otpušta adipozno tkivo i da ima endokrine funkcije koje učestvuju u otpornosti na insulin. Ova ideja prvenstveno proizilazi iz sudija kojima je pokazano da se nivoi serumskog rezistina povećavaju sa gojaznošću u nekoliko model sistema (ljudi, pacovi, i miševi).^[4]^[5]^[6]^[7]^[8] U međuvremenu dalja istraživanja su povezala rezistin sa drugim fiziološkim sistemima kao što je inflamacija i energetska homeostaza.^[9]^[10]^[11]

Reference уреди

^ PDB: 1rfx; Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L (2004). „Disulfide-dependent multimeric assembly of resistin family hormones”. Science. 304 (5674): 1154—8. PMID 15155948. doi:10.1126/science.1093466.
^ Wang H, Chu WS, Hemphill C, Elbein SC (2002). „Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians”. J. Clin. Endocrinol. Metab. 87 (6): 2520—4. PMID 12050208. doi:10.1210/jc.87.6.2520.
^ Lazar MA (2007). „Resistin- and Obesity-associated metabolic diseases”. Horm. Metab. Res. 39 (10): 710—6. PMID 17952831. doi:10.1055/s-2007-985897.
^ ^а ^б Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001). „The hormone resistin links obesity to diabetes”. Nature. 409 (6818): 307—12. PMID 11201732. doi:10.1038/35053000.
^ Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV (2003). „Serum resistin (FIZZ3) protein is increased in obese humans”. J. Clin. Endocrinol. Metab. 88 (11): 5452—5. PMID 14602788. doi:10.1210/jc.2002-021808.
^ Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N (2002). „Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?”. Diabetes. 51 (10): 2951—8. PMID 12351432. doi:10.2337/diabetes.51.10.2951.
^ Levy JR, Davenport B, Clore JN, Stevens W (2002). „Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats”. Am. J. Physiol. Endocrinol. Metab. 282 (3): E626—33. PMID 11832366. doi:10.1152/ajpendo.00346.2001.
^ McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S (2002). „Resistin, central obesity, and type 2 diabetes”. Lancet. 359 (9300): 46—7. PMID 11809189. doi:10.1016/S0140-6736(02)07281-1.
^ Adeghate E (2004). „An update on the biology and physiology of resistin”. Cell. Mol. Life Sci. 61 (19–20): 2485—96. PMID 15526156. doi:10.1007/s00018-004-4083-2.
^ Stumvoll M, Häring H (2002). „Resistin and adiponectin--of mice and men”. Obes. Res. 10 (11): 1197—9. PMID 12429885. doi:10.1038/oby.2002.162.
^ Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C (2004). „Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity”. Obes. Res. 12 (6): 962—71. PMID 15229336. doi:10.1038/oby.2004.118.

Spoljašnje veze уреди

Resistin на US National Library of Medicine Medical Subject Headings (MeSH)

[pmid15155948-1] PDB: 1rfx; Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L (2004). „Disulfide-dependent multimeric assembly of resistin family hormones”. Science. 304 (5674): 1154—8. PMID 15155948. doi:10.1126/science.1093466.

[pmid12050208-2] Wang H, Chu WS, Hemphill C, Elbein SC (2002). „Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians”. J. Clin. Endocrinol. Metab. 87 (6): 2520—4. PMID 12050208. doi:10.1210/jc.87.6.2520.

[pmid17952831-3] Lazar MA (2007). „Resistin- and Obesity-associated metabolic diseases”. Horm. Metab. Res. 39 (10): 710—6. PMID 17952831. doi:10.1055/s-2007-985897.

[p30-4] а ^б Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001). „The hormone resistin links obesity to diabetes”. Nature. 409 (6818): 307—12. PMID 11201732. doi:10.1038/35053000.

[p4-5] Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV (2003). „Serum resistin (FIZZ3) protein is increased in obese humans”. J. Clin. Endocrinol. Metab. 88 (11): 5452—5. PMID 14602788. doi:10.1210/jc.2002-021808.

[p8-6] Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N (2002). „Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?”. Diabetes. 51 (10): 2951—8. PMID 12351432. doi:10.2337/diabetes.51.10.2951.

[p16-7] Levy JR, Davenport B, Clore JN, Stevens W (2002). „Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats”. Am. J. Physiol. Endocrinol. Metab. 282 (3): E626—33. PMID 11832366. doi:10.1152/ajpendo.00346.2001.

[p19-8] McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S (2002). „Resistin, central obesity, and type 2 diabetes”. Lancet. 359 (9300): 46—7. PMID 11809189. doi:10.1016/S0140-6736(02)07281-1.

[p1-9] Adeghate E (2004). „An update on the biology and physiology of resistin”. Cell. Mol. Life Sci. 61 (19–20): 2485—96. PMID 15526156. doi:10.1007/s00018-004-4083-2.

[p31-10] Stumvoll M, Häring H (2002). „Resistin and adiponectin--of mice and men”. Obes. Res. 10 (11): 1197—9. PMID 12429885. doi:10.1038/oby.2002.162.

[p34-11] Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C (2004). „Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity”. Obes. Res. 12 (6): 962—71. PMID 15229336. doi:10.1038/oby.2004.118.

[2]

[1]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]